Eli Lilly announced a strategic partnership with Nvidia to establish a dedicated AI innovation laboratory, funded with an initial $1 billion commitment. The facility, to be located in Cambridge, Massachusetts, will focus on accelerating drug discovery through advanced machine learning models and high-performance computing clusters. Nvidia will supply cutting-edge GPUs and software tools, while Lilly will contribute proprietary biological datasets and medicinal chemistry expertise. The collaboration aims to shorten early-stage research timelines by up to 40%, with pilot programs targeting oncology and metabolic disease pipelines later this year.

Lilly has agreed to acquire Ventyx Biosciences for a total consideration of $600 million in cash, plus up to $200 million in regulatory and clinical milestones. Ventyx’s lead candidate, VTX-101, is a Phase II asset for treatment-resistant depression that demonstrated a 55% response rate in its latest interim analysis involving 120 patients. Lilly expects to integrate the VTX-101 program into its neuroscience portfolio immediately, aiming for a pivotal Phase III trial in mid-2025. The deal also adds two preclinical immuno-oncology compounds to Lilly’s research engine.

With the AI lab and Ventyx acquisition, Lilly is directing capital toward high-growth areas outside its established endocrinology franchises. Management projects a 2 to 3 percentage-point uplift in R&D productivity over the next three years, potentially driving a mid-single-digit increase in annual operating margin by 2027. The Ventyx deal is expected to be slightly dilutive to earnings per share in 2024 due to upfront payments but accretive from 2025 onward as milestone payments align with clinical readouts. Analysts have revised 2026 EPS growth forecasts from 8% to 11% following these developments.